Tag: F508del mutation

Traditionally, cystic fibrosis (CF) has been managed with treatments that address symptoms rather than the underlying cause. The emergence of Trikafta has revolutionized this approach, providing a targeted therapy that directly addresses the defective protein, significantly improving lung function and overall health for many with CF.

In a major advancement for cystic fibrosis (CF) care, the FDA approved Alyftrek in late 2024, and it became widely available in 2025, offering a significant upgrade for eligible patients. The question on many minds is, **what is the new CF drug 2025?** This once-daily triple-combination therapy simplifies treatment and continues the trend of targeted therapies that address the underlying cause of the disease.